• By Shin Hee Lee* and Anthony D. Sabatelli** —

    The global hair coloring product market is projected to grow into a 200 billion-dollar industry by 2025.  Coty reported in 2017 that more than half of all women color their hair regularly.  For example, these figures have reached 62% in the United States, 67% in the United Kingdom, 69% in Germany, and 88% in Russia.  An in-depth data analysis reported by Grand View Research, Inc. attributes this rapid growth to a global increase in the aging population, environmental insults such as air pollution, and new trends in the fashion industry.  Alongside the other lucrative sectors in the beauty industry that were discussed in our previous articles, "Patent Beauty: IP and the Cosmeceutical Industry" and "Patent Beauty: IP and Hair Care Products", the hair coloring sector also deserves a great amount of attention, especially in view of advancing technologies and the intellectual property covering it.

    Hair coloring products are categorized into three types:  temporary dyes, semi-permanent dyes, and permanent (oxidative) hair dyes.  Temporary dyes generally wash away after 1 or 2 shampooings because they only cover the surface of the hair.  Semi-permanent dyes penetrate into the hair shaft and can last up to 10 washings.  Permanent hair dyes chemically modify the hair shaft.  These dyes use oxidizing amines and phenols in combination with hydrogen peroxide to deliver penetrating dyes into the cortex of the hair.  Consumers can therefore choose the type of dye based on their needs, widely ranging from covering gray hair, creating highlights, providing subtle tone-up of the natural color, to performing a complete color transformation.  User-friendly coloring packs with step-by-step instructions are accessible for home use, whereas other consumers prefer having professional coloring done in a salon setting.

    Hair coloring products have a long history.  In ancient times people colored their hair with various plant extracts, but this often resulted in darkening the hair resulting in unpredictable colors.  Those seeking to lighten their hair resorted to harsh chemical treatments including caustic compounds.  In 1907, Eugene Schueller, a French chemist and founder of L'Oréal, introduced chemical hair dyes that enabled a large variety of colors and desirable results.  Coty, Henkel, Kao Corporation, Avon Products, Revlon, Goldwell, Wella, and Combe also joined the market and have become major vendors of hair coloring products.  These companies have not only been developing hair dye compounds, but also convenient methods for coloring the hair such as compact kits and specially designed dye applicators.

    Despite the effectiveness of chemical colorants, consumers have been concerned about hair damage as well as the potential health risks associated with their use.  These concerns have encouraged consumers to seek more natural and organic hair dyes.  A United States patent granted to the Natural Medicine Institute of Zhejiang Yangshentang in Hangzhou (US 9,345,654 B2) reports a natural dye product made of plant polyphenols, gardenia blue, cocoa pigment, purple sweet potato pigment, purple cabbage pigment or algae blue pigment.  A very intriguing hair dyeing composition was highlighted in the New York Times[1] a few months ago.  These compositions utilize graphene-based hair dyes developed by the Huang group of Northwestern University.  Graphene is a single atom thick layer of carbon in a molecular state, i.e., a very thin graphite layer.  It is a naturally dark material that creates a natural-looking black hair shade, something which has long been a challenge in the hair-dye industry.  This graphene hair dye is reported to exhibit durability comparable to permanent hair dyes, and may be more easily applied by spraying, brushing, and then drying.

    Natural and organic dyes are safe alternatives to existing synthetic dyes, but render a limited number of hair color options.  Researchers have been developing non-toxic synthetic dye molecules that are capable of achieving both safe and large array of hair colors.  Clairol, a Coty-owned brand, introduced an "allergy gentle" hair dye molecule called ME+ (2-methoxymethyl-p-phenylenediamine) in 2013.  It replaces two existing synthetic dye molecules (phenylenediamine and toluenediamine) that are in 90 percent of the permanent hair coloring products and which are believed responsible for most common hair dye allergies.

    Silicone technology and silicone-based polymers have found their way into a number of hair coloring products.  Many colorant packages include complementary conditioning and/or treatment hair conditioners comprised of silicone-based materials to minimize damage caused by the chemical dyes.  For example, the Procter & Gamble Company patented a process and kit for improved hair conditioning after coloring that utilizes functionalized silicones to condition oxidatively-treated hair (US 7,393.365 B2).  Procter & Gamble also disclosed a soluble solid hair coloring article containing, but not limited to, silicone-based polymers (US 8,444,716 B1).

    Today, the novelty hair colorant market is arguably one of the largest profit sectors within the hair coloring market.  This market is expected to grow at a fast compound annual growth rate of over 20%.  Vibrant, blonde, brown, red, paste, metallic, ombre, highlights, balayage (a graduated highlighting effect), color melting, and black are the main categories for these novelty products.  Even the names of the hair colors themselves are extending from conventional terminologies to creative ones such as Iced Caramel Latte, Blackberry, Hollywood Opal, Bright Butterbeer, and many more.  Phillip Pelusi, a hair care expert, recently stated that "besides mastering the formulation and application techniques, keeping the color molecules intact longer will be the next biggest challenge for stylists and guests alike."  Whether it is a temporary dye or a permanent dye, preserving a new hair color while keeping the hair healthy still remains a big challenge for hair coloring developers.  Below are some patents for various hair coloring technologies.

    Table 1a Table 1b

    [1] Kaplan, "In Search of the Perfect Hair Dye," posted on the New York Times — reports on newly discovered graphene-based pigments by Dr. Jianxing Huang of Northwestern University.

    * Shin Hee Lee is a Ph.D. Candidate in the Chemistry Department at Yale University.  She is currently associated with the Yale Energy Sciences Institute, where she specializes in organic synthesis of novel light-harvesting dye molecules for solar cells.  Prior to attending Yale, Shin Hee obtained her B.S. in Chemistry with High Honors at the University of Michigan – Ann Arbor, during which she published patents and papers on developing synthetic methodologies for fluorinated small molecules.
    ** Dr. Sabatelli is a Partner with Dilworth IP

    For additional information regarding this topic, please see:

    • "Patent Beauty: IP and the Cosmeceutical Industry," May 3, 2018
    • "Patent Beauty: IP and Hair Care Products," June 21, 2018

  • By Kevin E. Noonan —

    Red FoxThe red fox (Vulpes vulpes) has been the subject of a controlled breeding experiment in Russia, at the Institute of Cytology and Genetics of the Russian Academy of Sciences, to select for genetic determinants associated with domestication (principally, friendliness towards human beings; see, Dugatkin and Trut, 2017, How to Tame a Fox (and Build a Dog), University of Chicago Press).  The success of this program has provided a comparator for genetic experiments with conventional farm-bred red fox populations and aggressive foxes to identify these genes, as recently reported by an international group in Nature Genetics (see "Red fox genome assembly identifies genomic regions associated with tame and aggressive behaviours").  This study provides an interesting contrast with an earlier comparison (from a different group) between genomic DNA of the ancestral domesticated cat species, Felix sylvestris sylvestris and the common house cat Felis catus (see "Domestic Cat Genome Sequenced").

    In summary, the comparative study identified 103 chromosomal regions "with either significantly decreased heterozygosity in one of the three populations or increased divergence between the populations."  One particularly strong candidate to be a genetic determinant of "tame" behavior was identified as SorSC1, encoding the primary trafficking protein for AMPA glutamate receptors and neurexins in fox brain.  This result "suggests a role for synaptic plasticity in fox domestication," which seems reasonable.  Interestingly, other genes "likely to have been under selection" include those associated with neurological disorders in human beings, as well as genes previously identified as being involved in mouse behaviors and domestication in dogs (providing a compelling natural control group; the lineages of domesticated dogs and the red fox diverged about 10 million years ago, prior to domestication of Canis familiaris from the grey wolf about 15,000 years ago).  As the study notes, "[t]here is no evidence that the fox was domesticated historically," and indeed the fox has evolved to have the broadest geographic range of any member of the Carnivora.

    The study involved genomic DNA sequence comparisons of farm-bred foxes (which, while not still wild continue to exhibit fear or aggression towards humans) and two subsets of such foxes conditioned in diametrically opposed fashion for positive response to humans or aggression towards humans.  These animals have remained outbred throughout their development (~50 generations for friendly foxes and ~40 generations for unfriendly ones) and the foxes were otherwise not selected for any other traits (a distinction with the numerous dog breeds selected for many desired traits).  The genomic structure of foxes differs from the domesticated dog:  foxes have 16 pairs (38 pairs for dogs) of acrocentric (metacentric for dogs) autosomal chromosomes; each species has a pair of sex-determining chromosomes and the fox has an additional 0-8 supernumerary ("B") chromosomes.  These structural differences have made it difficult to compare fox and dog chromosomes histologically.

    This study provides genomic DNA assembly and annotation for the three types of foxes having three types of responses to humans.  The assembled fox genomic DNA revealed 21,418 protein coding genes and that 84% of the sequencing scaffolds map to one dog chromosome, 15% to two or more, and 1% could not be assigned.  A comparison of the three source genomes (10 foxes from each population) showed that there was "less divergence between the conventional and aggressive populations than between the tame and either the conventional or aggressive population" using single nucleotide polymorphism (SNP) comparisons (8,458,133 identified SNPs).  Of the 103 genomic regions identified as being associated with behavioral differences between these populations, "30 [were] identified in the tame population and 19 [were] identified in the aggressive population as showing a lower level of heterozygosity than would be expected due to genetic drift," and "[t]he longest regions were found on fox chromosomes 4, 8 and 14."

    Turning to genetic fine structure for genes associated with tameness or its opposite, the study showed that 80% of the genes detected were expressed in brain.  These included "[s]everal receptor-coding genes for glutamatergic (GRIN2B, GRM6), GABAergic (GABBR1, GABRA3, GABRQ) and cholinergic (CHRM3, CHRNA7) synapses."  Also detected were genes known to be associated with human neurological diseases (and hence related to behavior and changes therein), including "13 genes associated with autism spectrum disorder, 13 genes associated with bipolar disorder and three genes located at the border of the Williams–Beuren syndrome deletion in humans."  In addition, six fox genes were detected that had been implicated in aggressive behavior in mice.  Some of these genes were represented by alleles having missense mutations having different frequencies in the three populations, including "[t]wo missense mutations in the autism-associated CACNA1C gene, CACNA1C-SNP1 (Ile937Thr) and CACNA1C-SNP2 (Thr1875Ile), with the CACNA1C-SNP1 allele being found only in the tame population and the CACNA1C-SNP2 allele found in both the conventional and aggressive populations but not in the tame population."  The researchers also found that certain alleles of the SorCS1 gene were associated with interaction behavior that attracted attention after an interaction as opposed to avoidance, based on the presence of insertion/deletion (indel) markers in proximity of this gene.  The study shows identification of "one haplotype (olv) with a frequency of 60.6% in the tame population that was not observed in the aggressive population, two haplotypes (trq and lav) that were rare in tame but frequent in the aggressive population, and a fourth haplotype (pch) that was found in both populations."  The authors conclude that "[t]he function of SorCS1 as a global regulator of synaptic receptor trafficking supports the role of SorCS1 in the regulation of behavioural differences between tame and aggressive foxes."

    It seems apparent that such studies will be significant not only for identifying neurological changes that accompany domestication of animals, but also for better understanding genetic loci that may be implicated in human behaviors, including aggression.  Such understanding may lead to better ways to minimize the negative effects of unrestricted aggression in human populations.

    *Anna V. Kukekova, Jennifer L. Johnson, Xueyan Xiang, Shaohong Feng, Shiping Liu, Halie M. Rando, Anastasiya V. Kharlamova, Yury Herbeck, Natalya A. Serdyukova, Zijun Xiong, Violetta Beklemischeva, Klaus-Peter Koepfli, Rimma G. Gulevich, Anastasiya V. Vladimirova, Jessica P. Hekman, Polina L. Perelman, Aleksander S. Graphodatsky, Stephen J. O'Brien, Xu Wang, Andrew G. Clark, Gregory M. Acland, Lyudmila N. Trut & Guojie Zhang

    Image from British Wildlife Centre Wildlife by Airwolfhound, from the Wikimedia Commons under the Creative Commons Attribution-Share Alike 2.0 Generic license.

  •     By Bryan Helwig —

    Gavel_2About Life Sciences Court Report:  We will periodically report on recently filed biotech and pharma litigation.


    Horizon Therapeutics, LLC v. Par Pharmaceutical, Inc.
    1-18-cv-01224; filed August 10, 2018 in the District Court of Delaware

    • Plaintiff: Horizon Therapeutics, LLC
    • Defendants: Par Pharmaceuticals, Inc., Par Pharmaceutical Companies, Inc.

    Claim: Infringement of U.S. Patent No.

    • 8,642,012: "Methods of treatment using ammonia-scavenging drugs"

    Synopsis:  Horizon Therapeutics, LLC claims infringement of the ′012 patent for RAVICTI® (glycerol phenylbutyrate oral liquid 1.1gm/ml).  Horizion Therapeutics holds NDA No. 20324 for RAVICTI®, which is used as a nitrogen-binding agent for chronic management of adult and pediatric patients with urea cycle disorders.  Defendants, under ANDA No. 205742, seek approval to engage in the commercial manufacture, use, or sale of a generic version of RAVICTI® prior to the expiration of the '012 patent.

    View the complaint here.


    Allergan, Inc. v. Saptalis Pharmaceuticals, LLC
    1-18-cv-01231; filed August 10, 2018 in the District Court of Delaware (Wilmington)

    • Plaintiffs: Allergan, Inc. and Saint Regis Mohawk Tribe
    • Defendant: Saptalis Pharmaceuticals, LLC

    Claim: Infringement of U.S. Patent Nos.

    • 8,633,162: ″Methods of providing therapeutic effects using cyclosporin components"
    • 8,642,556: "Methods of providing therapeutic effects using cyclosporin components"

    Synopsis:  Allergan and Saint Regis Mohawk Tribe allege infringement of the ′162 and ′556 patents.  The Saint Regis Mohawk Tribe, as assignee, owns the entire right, title, and interest in the ′162 and ′556 patents.  Allergan is the holder of approved NDA No. 50-790 for Cyclosporine Ophthalmic Emulsion, 0.05%, sold under the RESTASIS® trademark.  Allergan holds an exclusive field-of-use license to the ʼ162 and ′556 patents with respect to commercializing RESTASIS®.  On information and belief, Saptalis submitted ANDA No. 211943 seeking FDA approval to engage in the commercial manufacture, use, importation, sale, or offer for sale of Cyclosporine Ophthalmic Emulsion, 0.05%, a generic version of Allergan's RESTASIS® product.  Plaintiffs seek declaratory judgment of Infringement of the ′012 and '556 patents.

    View the complaint here.


    AstraZeneca LP v. Hisun Pharmaceutical (Hangzhou) Co., Ltd.
    1-18-cv-01232; filed August 10, 2018 in the District Court of Delaware (Wilmington)

    • Plaintiffs: AstraZeneca LP, AstraZeneca AB, AstraZeneca UK Ltd., and AstraZeneca Pharmaceuticals LP
    • Defendants: Hisun Pharmaceutical (Hangzhou) Co., Ltd. and Hisun Pharmaceuticals USA, Inc.

    Claim: Infringement of U.S. Patent Nos.

    • 7,250,419: ″Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition″
    • 7,265,124: ″Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound″
    • RE46276: ″Triazolo(4,5-D)pyrimidine compounds″

    Synopsis:  AstraZeneca claims infringement of the ′419, ′124, and ′276 patents.  AstraZeneca is the holder of NDA No. 022433 for the marketing and sale of BRILINTA® (ticagrelor) tablets in 90 mg and 60 mg dosage strengths.  BRILINTA® is intended to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.  Hisun filed ANDA No. 208575 for commercial manufacture, use, and sale of generic ticagrelor tablets.

    View the complaint here.

    Related Cases: 15-cv-1042-RGA: AstraZeneca previously filed suit against Hisun regarding its ticagrelor ANDA and its proposed 90 mg dosage strength generic ticagrelor tablet. The parties later jointly dismissed the case without prejudice.


    Boehringer Ingelheim Pharmaceuticals, Inc. v. Lupin Atlantis Holdings SA
    3-18-cv-12663; filed August 10, 2018 in the District Court of New Jersey (Trenton)

    • Plaintiffs: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, and Boehringer Ingelheim Pharma GmbH & Co. KG
    • Defendants: Lupin Atlantis Holdings SA and Lupin Ltd.

    Claim: Infringement of U.S. Patent Nos.

    • 7,070,800: ″Inhalable Powder Containing Tiotropium″
    • 7,694,676: ″Dry Powder Inhaler″

    Synopsis:  Boehringer claims infringement of the ′800 and ′676 patents.  Boehringer is the holder of NDA No. 021395 for SPIRIVA® HandiHaler®, an anticholinergic indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations.  Lupin submitted ANDA No. 211287 to engage in the commercial manufacture, use, or sale of tiotropium bromide inhalation powder, 18 mcg/capsule, as a purported generic version of SPIRIVA® HandiHaler®.

    View the complaint here.


    AbbVie Inc. v. Sandoz Inc.
    3-18-cv-12668; filed August 10, 2018 in the District Court of New Jersey (Trenton)

    • Plaintiffs: AbbVie Inc., and Abbvie Biotechnology Ltd.
    • Defendants: Sandoz Inc., Sandoz GmbH, and Sandoz International GmbH

    Claim:  Infringement of U.S. Patent Nos.

    • 9,187,559: ″Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease″
    • 9,750,808: ″Formulation of human antibodies for treating TNF-Alpha associated disorders″

    Synopsis:  Abbvie Biotechnology Ltd. is the owner by assignment of the ′559 and ′808 patents.  AbbVie Inc. is the holder of Biologic License Application No. 125057 for HUMIRA®, whose active pharmaceutical ingredient is the antibody adalimumab.  Sandoz had submitted an abbreviated Biologics License Application ("aBLA") requesting that its biosimilar adalimumab product GP2017 be licensed for commercial sale by relying on AbbVie's demonstration that HUMIRA® is safe and effective.  Abbvie alleges that the aBLA provides Sandoz an abbreviated regulatory pathway for its biosimilar version of HUMIRA®, however in doing so Sandoz has infringed AbbVie's patents.

    View the complaint here.


    Athenex Pharma Solutions, LLC  v. Par Pharmaceutical, Inc.
    1-18-cv-00896; filed August 13, 2018 in the District Court Western District of New York (Buffalo)

    • Plaintiffs: Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC
    • Defendants: Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Co., LLC

    Claim: Infringement of U.S. Patent Nos.

    • 9,375,478: ″Vasopressin formulations for use in treatment of hypotension″
    • 9,687,526: ″Vasopressin formulations for use in treatment of hypotension″
    • 9,744,209: ″Vasopressin formulations for use in treatment of hypotension″
    • 9,744,239: ″Vasopressin formulations for use in treatment of hypotension″
    • 9,750,785: ″Vasopressin formulations for use in treatment of hypotension″
    • 9,937,223: ″Vasopressin formulations for use in treatment of hypotension″

    Synopsis:  Athenex seeks a declaration of non-infringement and invalidity of the ′478, ′526, ′209, ′239, ′785, and ′223 Patent.  Par Sterile is the manufacturer of Vasostrict® and is the holder of NDA No. 204485.  The active ingredient in Vasostrict® is vasopressin.  Athenex's compounded vasopressin products will be administered to patients in a ready-to-use form, eliminating the need for mixing by a health care professional.  As a result, Plaintiffs allege that their compounded vasopressin products do not, and would not, if marketed, infringe any claims of the patents in suit.

    View the complaint here.


    Valeant Pharmaceuticals v. Actavis Laboratories FL., Inc.
    1-18-cv-01288; filed August 22, 2018 in the District Court of Delaware (Wilmington)

    • Plaintiff: Valeant Pharmaceuticals International, Salix Pharmaceuticals Ltd., and Cosmo Technologies Ltd.
    • Defendant: Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd.

    Claim: Infringement of U.S. Patent No.

    • 10,052,286: ″Controlled release and taste masking oral pharmaceutical composition″

    Synopsis:  Valent claims infringement of the ′286 patent.  VPI holds NDA No. 203634 for oral tablets containing 9 mg of the active ingredient budesonide, which are sold in the United States under the brand name Uceris®.  Uceris® is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.  Actavis Labs submitted ANDA No. 205457 and seeks to engage in making, using, offering to sell and selling in the United States and/or importing into the United States its generic version of Uceris®.

    View the complaint here.


    Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.
    1-18-cv-01308; filed August 23, 2018 in the District Court of Delaware (Wilmington)

    • Plaintiffs: Insys Therapeutics, Inc. and Insys Development Co., Inc.
    • Defendants: Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.

    Claim: Infringement of U.S. Patent Nos.

    • 8,486,972:  ″Sublingual fentanyl spray″
    • 8,486,973: ″Sublingual fentanyl spray″
    • 8,835,459: ″Sublingual fentanyl spray″
    • 8,835,460: ″Sublingual fentanyl spray and methods of treating pain″
    • 9,241,935: ″Sublingual fentanyl spray″
    • 9,289,387: ″Method of treating pain by administering sublingual fentanyl spray″
    • 9,642,797:  ″Sublingual fentanyl spray and methods of use to treat pain″
    • 9,642,844: ″Sublingual fentanyl spray″

    Synopsis:  Insys claims infringement of the ′972, ′973, ′459, ′460, ′935, ′387, ′797, and ′844 patents.  Insys holds NDA No. 202788 on SUBSYS®, a fentanyl sublingual spray, and is the exclusive distributor of SUBSYS® in the United States.  Defendants, under ANDA No. 211209 have indicated they intend to engage in the commercial manufacture, use, or sale of a Fentanyl Sublingual Spray, 0.8 mg before the expiration of the patents-in-suit.

    View the complaint here.

  • CalendarSeptember 6, 2018 – "From BRI to Phillips at the PTAB: Consequences for Practice" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    September 11, 2018 – "How Notre Dame's IDEA Center Took University Start-Up Formation from Puny to Powerhouse: A Case Study in Performance Improvement" (Technology Transfer Tactics) – 1:00 pm to 2:00 pm (ET)

    September 12, 2018 – "Evolving PTAB Trial Practice: Navigating Complex Procedural Rules — Strategically Using Routine and Additional Discovery, Requests for Joinder, and Motions to Amend" (Strafford) – 1:00 to 2:30 pm (EDT)

    September 13, 2018 – "Blockchain and IP: Navigating Emerging Issues — Blockchain, DLT Platforms, Crypto-Tokens, Smart Contracts, and More" (Strafford) – 1:00 to 2:30 pm (EDT)

    September 14, 2018 – "Trade Secrets: What Every IP Attorney and In-house Counsel Should Know" (John Marshall Law School Center for Intellectual Property, Information & Privacy Law ) – 9:00 am to 4:30 pm, Chicago, IL

    September 18, 2018 – "The Continued Influence of PTAB Proceedings on Bio/Pharma Patents" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    September 21, 2018 – "USPTO Post-Grant Patent Trials 2018: Change & Recalibration" (Practising Law Institute) – New York & Groupcasts in Philadelphia, Indianapolis, New Brunswick, NJ, Pittsburgh, and Mechanicsburg, PA

    September 26, 2018 – "IP Audit Checklist: Best Practices to Identify, Protect, Monetize and Enforce University IP Assets" (Technology Transfer Tactics) – 1:00 pm to 2:00 pm (ET)

    September 27-28, 2018 – "Advanced Patent Prosecution Workshop 2018: Claim Drafting & Amendment Writing" (Practising Law Institute) – Chicago, IL

    September 27-28, 2018 – FDA Boot Camp (American Conference Institute) – Boston, MA

    October 2, 2018 – "Advice of Counsel Defense in Patent Litigation and Protecting Attorney-Client Privilege — Limiting Scope of Discovery, Safeguarding Confidential Communications and Information" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 2-3, 2018 – Paragraph IV Disputes master symposium (American Conference Institute) – Chicago, IL

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "From BRI to Phillips at the PTAB: Consequences for Practice" on September 6, 2018 from 2:00 to 3:00 pm (ET).  Eric Cohen of Brinks Gilson & Lione, Kevin Greenleaf of Dentons US LLP, and Shaun Zang of Goldman Ismail Tomaselli Brennan & Baum LLP examined dozens of litigations in recent years where both district courts and the PTAB construed the same patents, and will provide useful insights as the PTAB is expected to switch from BRI to Phillips in post-grant proceedings this fall.  The panel will also give tips on how both patent owners and petitioners should proceed in the interim, and discuss other ramifications of the change, such as:

    • Deciding on a proposed claim construction will require even more care, because there will no longer be an opportunity to take differing positions at the PTAB and district court, now a frequent and often successful litigation strategy
    • That defendants in litigation can expect to be able to mount stronger non-infringement positions as a uniform and narrower claim interpretation makes it less likely the accused device will infringe
    • The potential fallout from the PTAB adopting a standard for AIA proceedings that differs from the one used in all other USPTO proceedings, such as reexamination and reissue.

    The registration fee for the webinar is $135 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Advice of Counsel Defense in Patent Litigation and Protecting Attorney-Client Privilege — Limiting Scope of Discovery, Safeguarding Confidential Communications and Information" on October 2, 2018 from 1:00 to 2:30 pm (EDT).  Krupa K. Parikh of Latham & Watkins, April E. Weisbruch of Sheppard Mullin Richter & Hampton, and Eleanor M. Yost of Carlton Fields Jorden Burt will provide patent counsel with an examination of the role of the advice of counsel defense in patent infringement cases in the aftermath of Halo, and the temporal and subject matter scope of the potential waiver of the attorney-client privilege and work product protection when an accused infringer relies upon such a willfulness defense.  The panel will also discuss recent decisions and offer guidance to counsel and companies for protecting privileged communications and attorney work product when relying upon an advice of counsel defense.  The webinar will review the following issues:

    • What is the practical impact of recent Supreme Court and federal court decisions on utilizing opinions of counsel in defense of willful infringement while protecting privileged communications and attorney work product?
    • What considerations regarding possible waiver of the attorney-client privilege and work product immunity should counsel consider before asserting the advice of counsel defense in patent infringement litigation?
    • What are the best practices for counsel and corporations to preserve the attorney-client privilege and work product immunity?

    The registration fee for the webcast is $297.  Those registering by September 14, 2018 will receive a $50 discount.  Those interested in registering for the webinar, can do so here.

  • Technology Transfer Tactics will be offering a webinar entitled "IP Audit Checklist: Best Practices to Identify, Protect, Monetize and Enforce University IP Assets" on September 26, 2018 from 1:00 pm to 2:00 pm (ET).  Jonathan Wachs, Gregory Grissett, Robert Katz, Scott Lloyd of Offit Kurman will take attendees step-by-step through the process and procedures of a general audit, event-driven audit, and limited-purpose IP audit.  They will also cover the following topics:

    • Tracking and maintaining regulatory upkeep on your IP assets
    • Understanding where your IP strengths and weaknesses are
    • Identifying IP for potential bundling and packaging for monetization
    • Realizing the value of your portfolio
    • Identifying risk areas that could trigger enforcement actions
    • Assessing risk of PTAB IPR and other challenges to validity
    • Understand what industry and licensees are looking for in high-quality IP assets

    The registration fee for the webinar is $197.  Those interested in registering for the webinar, can do so here.

    Technology Transfer Tactics

  • Intent Matters in Safe Harbor under BPCIA

    By Kevin E. Noonan —

    District Court for the District of DelawareEarlier this week, Judge Richard G. Andrews, U.S. District Court Judge for the District of Delaware decided a veritable plethora of post-trial motions (by both parties) in Amgen Inc. v. Hospira, Inc. (he denied them all).  These included Hospira's Rule 50(a) Motion for Judgment as a Matter of Law on the Issues of Safe Harbor, Noninfringement, Invalidity, and Damages and related briefing, Hospira's Motion for Judgment as a Matter of Law Under Rule 50(b) and, in the Alternative, For Remittitur or New Trial Under Rule 59 and related briefing, Hospira's Motion to Seal Confidential Exhibits Admitted at Trial and related briefing, Amgen's Renewed Motion for Judgment as a Matter of Law of Infringement of the '349 Patent or, in the Alternative, for a New Trial and related briefing, and Amgen's Motion for Prejudgment and Post-judgment Interest and related briefing.  Of note is the basis for the Court's denial of Hospira's safe harbor motion under the provisions of the Biologics Price Competition and Innovation Act (BPCIA).

    The case arose over Amgen's complaint that Hospira infringed its U.S. Patent Nos. 5,865,298 and 5,756,349.  The jury found that Hospira had not carried its burden of showing either patent to be invalid by clear and convincing evidence; that Hospira infringed claims 24 and 27 of the '298 patent but had not infringed claims 1-7 of the '349 patent:

    '298 patent claims at issue:

    24.  A method of preparing erythropoietin molecules having a predetermined number of sialic acids per molecule said number selected from the group consisting of 1-14, comprising applying material containing erythropoietin to an ion exchange column and selectively eluting said molecules from the column.

    27.  A method for obtaining an erythropoietin composition having a predetermined in vivo specific activity comprising preparing a mixture of two or more erythropoietin isoforms of claim 1.

    Where independent claim 1 recites:

    1.  An isolated biologically active erythropoietin isoform having a single isoelectric point and having a specific number of sialic acids per molecule, said number selected from the group consisting of 1-14, and said isoform being the product of the expression of an exogenous DNA sequence in a non-human eucaryotic host cell.

    '349 patent claims at issue:

    1.  Vertebrate cells which can be propagated in vitro and which are capable upon growth in culture of producing erythropoietin in the medium of their growth in excess of 100 U of erythropoietin per 106 cells in 48 hours as determined by radioimmunoassay, said cells comprising non-human DNA sequences which control transcription of DNA encoding human erythropoietin.

    2.  Vertebrate cells according to claim 1 capable of producing in excess of 500 U erythropoietin per 106 cells in 48 hours.

    3.  Vertebrate cells according to claim 1 capable of producing in excess of 1000 U erythropoietin per 106 cells in 48 hours.

    4.  Vertebrate cells which can be propagated in vitro which comprise transcription control DNA sequences, other than human erythropoietin transcription control sequences, for production of human erythropoietin, and which upon growth in culture are capable of producing in the medium of their growth in excess of 100 U of erythropoietin per 106 cells in 48 hours as determined by radioimmunoassay.

    5.  Vertebrate cells according to claim 4 capable of producing in excess of 500 U erythropoietin per 106 cells in 48 hours.

    6.  Vertebrate cells according to claim 4 capable of producing in excess of 1000 U erythropoietin per 106 cells in 48 hours.

    7.  A process for producing erythropoietin comprising the step of culturing, under suitable nutrient conditions, vertebrate cells according to claim 1, 2, 3, 4, 5 or 6.

    The Court also assessed damages in the amount of $70 million, inclusive of pre- and post-judgment interest.

    Hospira contended that the jury instructions were "legally erroneous and prejudicial," inter alia, because "ulterior motives and intent are irrelevant to [entitlement to] the Safe Harbor."  Specifically, Hospira argued that the instructions did not clarify the use of the terms "use" and "make" as relevant to whether an activity was entitled to the safe harbor provisions of the statute.  ("We would urge the broader standard for uses, but focus on the instruction should be on the uses and not the motives or purposes in making [a] batch.  The statutory exemption is premised on the use aspect.")  According to Hospira, the jury was asked to determine whether "manufacture" of the accused infringing article (biosimilar erythropoietin, bEPO) fell under the safe harbor when the only burden Hospira rightfully was obliged to meet was whether "use" of the allegedly infringing bEPO was "reasonably related to obtaining FDA approval."  The Court disagreed, stating that "Hospira's potentially infringing 'use' of Amgen' s patented invention is Hospira's manufacture of the EPO drug substance referred to in its BLA (i.e., Hospira's performance of the steps of Amgen's method claims), not Hospira's subsequent use of the EPO drug substance (i.e., Hospira's subsequent use of the product obtained by practicing Amgen's method claims)."  Thus, the safe harbor is available to Hospira only if manufacture of its bEPO was "reasonably related to obtaining FDA approval."  Hospira's subsequent use of the bEPO is "probative in determining whether Hospira's manufacture of its EPO drug substance was reasonably related to obtaining FDA approval, [but] it is the manufacture itself (not Hospira's subsequent uses of EPO drug substance) that is the potentially infringing act which must be evaluated for safe harbor protection."

    In addition, Hospira argued that it was unduly prejudicial for the Court not to instruct the jury that "intent is irrelevant to evaluating safe harbor protection."  The Court interpreted Hospira's position to be that "intent is entirely irrelevant to the safe harbor analysis" but with that the judge expressly disagreed as being unsupported by the cited case law.  Specifically, the Memorandum Opinion interprets Abtox, Inc. v. Exitron Corp., 122 F.3d 1019 (Fed. Cir. 1997), to mean that a party can use the benefit of the safe harbor "to use its data from the tests for more than FDA approval" and "does not look to the underlying purposes or attendant consequences of the activity (e.g., tests led to the sale of the patent), as long as the use is reasonably related to FDA approval" but "did not state that intent was irrelevant in determining whether an activity is reasonably related to obtaining FDA approval."  On the contrary, the opinion states that "evidence of intent can be a relevant factor in determining whether an activity is reasonably related to obtaining FDA approval, and that these cases stand for the proposition that evidence of commercial intent is not determinative of the safe harbor inquiry."  "[O]nce it is determined that 'the activity is reasonably related to obtaining FDA approval,' [] intent or alternative uses are irrelevant to its qualification to invoke the section 271(e) shield," according to the opinion.  And further:

    [A]dopting Hospira's interpretation of the safe harbor defense would expand the defense beyond recognition and create a loophole that would make it virtually impossible to prove infringement in cases involving products regulated by the FDA.  Since Hospira's interpretation requires ignoring intent in deciding whether the safe harbor applies, a party could manufacture 200 drug substance batches and earmark them for future use as commercial inventory without infringing, so long as the party used each of those batches for at least one test to generate data of the type used by the FDA in determining whether to approve the drug.  In that scenario, each batch would be tested to generate data that could conceivably be used to respond to inquiries from the FDA, making each batch reasonably related to obtaining FDA approval.  Essentially, Hospira's interpretation allows a single "token" submission of information derived from a potential infringing act to exempt that act from infringement, without regard to the realities surrounding the potentially infringing act.  It seems to me that Hospira's interpretation reads the words "solely" and "reasonably" out of the statute, and that a party's stated intent may be considered as part of whether the manufacture or use of a patented drug was "solely for uses reasonably related to" obtaining FDA approval.  I think that the jury instructions properly recited the role of intent in the safe harbor analysis.

    The hypothetical nicely illustrates the practical considerations behind the scope of the safe harbor, and how these considerations influence how courts evaluate the safe harbor's proper scope.

    Amgen Inc. v. Hospira, Inc. (D. Del. 2018)
    Memorandum Opinion by Judge Andrews

  • Claims for Displaying Message Timing Data Found Patent Ineligible

    By James Korenchan —

    District Court for the Central District of CaliforniaLast week, the U.S. District Court for the Central District of California ruled that claims related to providing time data for messages communicated between electronic devices in a messaging conversation are patent ineligible under 35 U.S.C. § 101.

    Back in March, BlackBerry Limited ("BlackBerry") filed suit against Facebook, Inc., WhatsApp, Inc., Instagram, Inc., and Instagram, LLC (collectively, "Facebook Defendants"), alleging infringement of nine patents.  BlackBerry then sued Snap, Inc. ("Snap") a month later alleging infringement of six of those nine patents.  The Defendants in each of these suits each moved to dismiss their respective cases.  Snap moved on the basis that each of the six asserted patents are patent-ineligible.  The Facebook Defendants moved on the basis that four of the nine asserted patents in that suit are patent-ineligible.  The Court's ruling addressed seven of the nine patents, three of which were common between the two suits.  In particular, the Court granted Snap's motion with prejudice as to the independent claims of asserted U.S. Patent No. 8,301,713 (the '713 patent) and otherwise denied all other motions, including Snap's movement with respect to the dependent claims of the '713 patent.  This post addresses only the ruling on the '713 patent.

    The '713 patent is directed to handheld electronic devices and providing information related to timing of messages (e.g., instant messages) in a messaging conversation.  The patent describes how handheld electronic devices have limited space for displaying information, which can make it difficult to provide a user with various time data related to the user's conversations.  The patent particularly aims to provide time data in scenarios where there are gaps between messages in a conversation.  For example, User 1 may send a message to User 2, but User 2 may not respond to the message immediately.  In this scenario, the patent purports to have User 1's electronic device determine that a predetermined duration of time (e.g., ten minutes) has elapsed since User 1's message was sent and that no other messaging has occurred since User 1's message was sent.  If after this duration elapses User 1's device detects an input, such as a message that User 1 is preparing to send to resume the conversation, the device will display a time at which the input occurred.  The patent describes other timing aspects of the conversation that can be provided as well, some or all of which can be provided to the user upon specific request.

    Representative claim 1 of the '713 patent is shown below.  The other independent claims recite similar language.

    1.  A method of operating an electronic device, the method comprising:
        outputting an electronic conversation comprising a plurality of indications, each indication being representative of at least a portion of a corresponding messaging communication between the electronic device and a second electronic device;
        identifying a first messaging communication between the electronic device and the second electronic device occurring at a first time, the first messaging communication having a corresponding first indication representative of at least a portion of the first messaging communication and which is one of the plurality of indications;
        determining that a predetermined duration of time has elapsed since the first time without additional communication between the electronic device and the second electronic device during that duration of time;
        detecting an input to the electronic device following said identifying and determining steps, said input occurring at a second time; and
        responsive to said detecting an input, outputting in the electronic conversation, a time stamp representative of the second time.

    With respect to Alice step one, Snap argued that the '713 patent is directed to the abstract idea of time stamping, which Snap noted is an "utterly unremarkable idea that has been practiced manually for centuries."  (Snap also pointed out that BlackBerry's complaint itself acknowledges that time stamping electronic messaging was already well-known.)  In addition, Snap argued that time stamping communications after a predetermined duration is well-known, and that the '713 patent provided no limitations of what the duration would be.  Finally, Snap noted that, although the '713 patent describes how the purported invention was useful for saving space on devices with small screens, the asserted claims were not limited to devices with small screens.

    In response, BlackBerry asserted that its invention "mak[es] a specific improvement to the way that time stamp information is displayed in an electronic conversation on a computer, specifically by displaying a timestamp when the user is most likely to be interested in one, rather than never displaying a timestamp (which under-informs users) and displaying a timestamp with each message (which unduly takes up valuable real estate and annoys users)" (emphasis in original).  BlackBerry also argued that the provisional patent leading to the '713 patent demonstrated that the '713 patent claims were directed to optimizing instant messaging for devices with small screens.

    Despite BlackBerry's opposition, the Court pointed out that the '713 patent doesn't provide any information that specifically defines how or where to display a timestamp.  The Court also agreed with Snap (and BlackBerry effectively conceded) that the '713 patent did not limit what the predetermined duration of time could be, and thus the duration could be anything.  Thus, the language of claim 1 was broad enough to encompass embodiments in which no improvements to timestamping messages were provided.  As the Court noted, the Federal Circuit has previously found that use of a rule alone does not necessarily make a set of claims non-abstract.  Here, the "predetermined duration of time" aspect of the claim, while a rule, hardly qualified as a rule to elevate the claim into the realm of patent-eligibility.  At best, BlackBerry characterized the claims as only inserting a time stamp when there is a "break" in the conversations, but the claims still do not address specific lengths of the break.  The Court concluded that the independent claims were directed to the abstract idea of "displaying a timestamp based on the rule of whether a predetermined duration of time has passed."

    The Court then went on to briefly discuss Alice step two.  The Court stating that, in contrast to BlackBerry's assertion that selective timing — namely, the "predetermined duration of time" aspect of the claim — was an inventive concept, this aspect was part of the abstract idea itself, and thus is not considered in performing the step two analysis.  The Court also noted the presence of "generic computer elements" in the independent claims.

    Although Snap asserted in its motion that the independent claims are representative of all claims of the '713 patent, the Court was not ready to doom the dependent claims, finding that Snap did not meet its burden of patent ineligibility with respect to those claims.  Still, it is hard to see the dependent claims surviving.  (Concepts covered by the dependent claims define the claimed "input" as a "resumption message" resuming the conversation, display the resumption message, and display the time stamp between the resumption message and the previous message in the conversation.)

    BlackBerry Ltd. v. Facebook, Inc. (C.D. Cal. 2018)
    In Chambers – Final Ruling on Facebook Defendant's Motion to Dismiss by District Judge Wu

  • By Kevin E. Noonan —

    USPTO SealPatent law has traditionally been considered to be fraught with traps for the unwary, which in practice just means that it is unwise to assume anything (see Carl S. Koening, "Clarifying Patent Terminology and Patent Concepts – An Introduction to Some Basic Concepts and Doctrine," 15 Cath. U. L. Rev. 1 (1966)).  Petitioner for an inter partes review proceeding, Vizio, Inc., v. ATI Technologies ULC suffered the consequences of one of those traps, when its petition for review of U.S. Patent No. 7,633,506 was deemed untimely under 35 U.S.C. § 315(b) because the petition was not filed within one year of Patent Owner filing suit against Petitioner Vizio.  While a seemingly simple docketing matter, in this case the error arose over when (i.e., what date) the complaint was filed.

    As set forth in the Board's Decision denying institution, the facts are these.  Vizio filed its IPR petition on February 1, 2017, one year after receiving the complaint.  Patent Owner filed an affidavit of service, establishing that Patent Owner had mailed the complaint to Vizio on January 30, 2017.  The question before the Board was whether the one-year time period under § 315(b) for filing an IPR petition ran from the date of mailing by Patent Owner or the date of receipt of the complaint by Petitioner Vizio.

    To answer this question, the Board looked to Federal Rule of Civil Procedure 4(h)(1)(A), which states that a corporation is served "in the manner prescribed by Rule 4(e)(1) for serving an individual."  Fed. R. Civ. P. 4(e)(1) states that service on an individual under the Rules is done "following state law for serving a summons in an action brought in courts of general jurisdiction in the state where the district court is located" (or where service is made).  Thus, the Board reasoned, the time and manner where service was accomplished was a matter of Delaware law (where the Patent Owner was incorporated).

    Turning to Delaware law, service can be made "by any form of mail addressed to the person to be served and requiring a signed receipt," citing 10 Del. C. § 3104(d)(3).  The Delaware civil procedure rules provide, in particular, that "[s]ervice by mail is complete upon mailing."  Del. R. Civ. P. 5(b), which is consistent with the statutory predicate that "the time in which defendant shall serve an answer shall be computed from the date of the mailing which is the subject of the return receipt or other official proof of delivery."  10 Del. C. § 3104(g).

    Thus, the Board determined that:

    Applying the Delaware statutes and rules regarding service to the facts of this case, Patent Owner served Petitioner with a copy of the summons and complaint, in compliance with § 3104, with a date of mailing of January 30, 2017.  Petitioner filed the instant petition for inter partes review on February 1, 2018, which is more than one year after Petitioner was served with a complaint alleging infringement of the '506 Patent.  Accordingly, Petitioner's petition is time-barred under § 315(b) and inter partes review may not be instituted.

    In practice, the lesson is clear:  when calculating the bar date under § 315(b) for filing an IPR the service rules in the state where the district court resides must be consulted because the service date recognized in that state for civil actions will be dispositive for the date where the one-year term begins (and ends in the bar date).  As service rules vary from state-to-state, there is clearly no "one size fits all" answer to the bar date determination, creating yet another trap for practitioners (which should be alleviated by this decision).

    In this case, all may not be lost.  According to the Decision, three other IPR petitions have been filed by "entities unrelated to Vizio," and Vizio has filed a petition for IPR on a related patent (U.S. Patent No. 7,796,133).  Both District Court and International Trade Commission proceedings are also on-going between the parties.

    Vizio, Inc., v. ATI Technologies ULC (PTAB 2018)
    Panel: Administrative Patent Judges Hoff, Change, and McNamara
    Decision by Administrative Patent Judge McNamara